SCHEMBL679839

SCHEMBL679839

Cc1ccc(Cn2nc3c(c2Sc2ccccc2)c(=O)n(C)c(=O)n3C2CCCC2)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 9/20 0.35
PIK3CA P42336 5/20 0.35
MTOR P42345 2/20 0.35
PDE4A P27815 1/20 0.35
TNF P01375 1/20 0.34
LITAF Q99732 1/20 0.34
LMNA P02545 2/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
THRB P10828 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
MAPK1 P28482 2/20 0.33
TSHR P16473 2/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15943433 0.90 PDE4A (0.39) PRKDCPIK3CAMTORPDE4ATNF
SCHEMBL678943 0.83 PDE4A (0.35) PRKDCPIK3CAPDE4ALMNACRHBP
SCHEMBL678927 0.82 PDE1B (0.44) PDE1APDE1BPDE1C
SCHEMBL2612352 0.77 PDE1B (0.43) PRKDCPIK3CAMTORPDE4APDE1A
SCHEMBL15943450 0.73 PDE1B (0.45) PDE1APDE1BPDE1C
SCHEMBL9608346 0.70 PRKDC (0.49) PRKDCPIK3CAMTOR
SCHEMBL676517 0.68 PDE1B (0.54) PDE4ALMNANPSR1PDE1APDE1B
SCHEMBL674429 0.68 ALDH1A1 (0.43) LMNATHRBL3MBTL1MAPK1
SCHEMBL678934 0.67 PDE1B (0.40) PDE4APDE1APDE1BPDE1CJAK3
SCHEMBL194043 0.67 PDE1B (0.58) PRKDCPIK3CAPDE4APDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487527-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I INTRA-CELLULAR THERAPIES, INC. (US) 2016-11-08 US disclosed
US-20150119370-A1 Organic Compounds LI PENG (US) 2015-04-30 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281832-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 PRKDC 3018/4885PIK3CA 269/4885MTOR 337/4885
US-20150119370-A1 Organic Compounds CYP2C19, CYP2C9, CYP3A43 PRKDC 4127/4885PIK3CA 1265/4885MTOR 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.